{"schema_version":"1.0","type":"article","title":"慢性阻塞性肺病患者又有新藥可以用了？","url":"https://drugnews.com.tw/articles/2026-04-23-dcard-261352566.html","markdown_url":"https://drugnews.com.tw/articles/2026-04-23-dcard-261352566.md","lang":"zh-Hant","date":"2026-04-23","publish_at":"2026-04-23T10:30:00+08:00","updated_at":"2026-04-23","category":"商業分析系列","topic":"商業分析系列","tags":["商業分析系列","免費文章","自體免疫","BD","臨床數據","生技投資","製藥巨頭"],"summary":"2025 年，對 IL-33/ST2 這條曾被寄予厚望的發炎路徑而言，幾乎是一整年的信心潰散。","key_points":[],"facts":[],"sections":["🔹 IL-33 靶點從連番受挫到強勢翻盤，Tozorakimab 為何能一戰翻身","✨ 為什麼 IL-33 一直讓人放不下","🧬 Tozorakimab 真正贏在哪裡？","📈 這不只是翻身，而是整個賽道重新被打開","🚀 下一輪戰爭，已經不是單抗而已","🧭 真正的結論：不是 IL-33 不行，而是你要更懂它"],"references":[{"title":"[0]: 公開資料＆各公司官網","source":"","date":"","url":""},{"title":"[1]:","source":"","date":"","url":""},{"title":"Sanofi","source":"","date":"","url":""},{"title":"Itepekimab met the primary endpoint in one of two COPD phase 3 studies AERIFY-1 study met its primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former...","source":"","date":"","url":""},{"title":"www.sanofi.com","source":"","date":"","url":""},{"title":"[2]:","source":"","date":"","url":""},{"title":"Shining a spotlight on COPD - raising awareness through media workshops","source":"","date":"","url":""},{"title":"One factor that influences levels of public awareness on different health issues is the amount of media coverage the topic receives. COPD is rarely reported in the media and the stories of those living with this common, serious condition often remain unto","source":"","date":"","url":""},{"title":"www.who.int","source":"","date":"","url":""},{"title":"[3]:","source":"","date":"","url":""},{"title":"www.astrazeneca.com","source":"","date":"","url":""},{"title":"https://www.astrazeneca.com/media-centre/press-releases/2026/tozorakimab-met-primary-endpoint-in-oberon-titania-phase-iii-trials-in-patients-with-copd.html","source":"","date":"","url":"https://www.astrazeneca.com/media-centre/press-releases/2026/tozorakimab-met-primary-endpoint-in-oberon-titania-phase-iii-trials-in-patients-with-copd.html"},{"title":"www.astrazeneca.com","source":"","date":"","url":""},{"title":"[4]:","source":"","date":"","url":""},{"title":"[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on astegolimab in chronic obstructive pulmonary disease","source":"","date":"","url":""},{"title":"The pivotal phase IIb ALIENTO study met the primary endpoint of a statistically significant reduction in the annualised exacerbation rate (AER) at 52 weeks when astegolimab was given every two...","source":"","date":"","url":""},{"title":"www.roche.com","source":"","date":"","url":""},{"title":"[5]:","source":"","date":"","url":""},{"title":"Close banner","source":"","date":"","url":""},{"title":"Interleukin (IL)-33 is a broad-acting alarmin cytokine that can drive inflammatory responses following tissue damage or infection and is a promising target for treatment of inflammatory disease. Here, we describe the identification of tozorakimab (MEDI350","source":"","date":"","url":""},{"title":"www.nature.com","source":"","date":"","url":""}],"images":[{"alt":"Dcard 原圖：慢性阻塞性肺病患者又有新藥可以用了？（圖 1）","url":"https://drugnews.com.tw/assets/articles/dcard-261352566/dcard-01.webp"},{"alt":"Dcard 原圖：慢性阻塞性肺病患者又有新藥可以用了？（圖 2）","url":"https://drugnews.com.tw/assets/articles/dcard-261352566/dcard-02.webp"},{"alt":"Dcard 原圖：慢性阻塞性肺病患者又有新藥可以用了？（圖 3）","url":"https://drugnews.com.tw/assets/articles/dcard-261352566/dcard-03.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/dcard-261352566/dcard-01.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-04-23）。慢性阻塞性肺病患者又有新藥可以用了？。https://drugnews.com.tw/articles/2026-04-23-dcard-261352566.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-04-23-dcard-261352566-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}